Clinical Trial Search

Primary: Number of Impedance Episodes Following PPI and Placebo — 47; 53 number of episodes

Primary: Number of Transient Lower Esophageal Sphincter Relaxations (TLESRs) 0-3 Hours Post Meal, Post Third Dose — 11.6; 15.5 Relaxations

Primary: Total Number of Reflux Episodes During 24 Hours — 59.4; 50.7; 44.3; 38.0 Episodes

Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants

Primary: Absence of Recurrence of Reflux Esophagitis According to Los Angeles Classification Throughout the Treatment Period. — 174; 166; 156 Participants

Primary: Patient-reported Symptom Response to Treatment Measured by the Reflux Symptom Index (RSI) Score — 15.5 score on a scale

Primary: Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los…

Primary: Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention — -1.2397; 0.0869 scores on a scale — p=0.0002

Primary: Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks — -54.3 Per Cent Change — p=<0.05

Primary: The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period…

Primary: Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12…

Primary: Patient's Assessment of Stanford Sleepiness Scale for the Last 24 Hours (Diaries) — 2.94; 2.62; 2.28; 2.03 Units on a scale

Primary: Percentage of Patients With Relief of Nighttime Heartburn During the Last 7 Days of the Study. — 34.3; 10.4 Percentage of participants

Primary: Assessment of the Severity of Sleep Disturbances — 13.8; 77.4; 38.2; 20.0 percentage of participants

Primary: Bradycardia Episodes/Day — 4.6; 3.6 episodes per day

Primary: Change in Frequency of Days With Heartburn From Baseline to 8 Weeks of Treatment — -3.44 Days per week with symptoms

Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28

Primary: Histological Response to Treatment — 11; 16; 7; 12 Participants — p=1.00

Primary: Number of Participants in Each Level of Wheeze Control — 18; 11; 9 Participants

Primary: Gastroesophageal Reflux Disease Health Related Quality of Life Outcome (GERD-HRQL) — 4.2; 4.9 score on a scale

Primary: Patient's Assessment of General Well-being During the Last 24 Hours (Diaries; ReQuest™ in Practice) — 5.31; 4.60; 3.67; 2.95 Units on a scale

Primary: Decrease in pH From Baseline to <4 — 1.1; 3.2; 3.8 distal esophagus total % time pH <4 — p=.05

Primary: Salivary Pepsin Concentration — 158.4 ng/mL — p=0.61

Primary: Symptom Control Rate at 24 Weeks Assessed by Gerd Q Questionnaire. — 94.9; 87.3 percentage of participants

Primary: Change From Baseline in Reflux Disease Symptom - Heartburn — 59; 117; 186; 7 participants

Primary: Time to First Pulmonary Exacerbation — NA; NA Weeks

Primary: Episodes of Poor Asthma Control (EPAC) From Diary Cards, According to Definition That Did Not Include Use of Beta-agonists as a Criterion — 2.3; 2.5 events per person…

Primary: TRPV1, GDNF, and NGF mRNA Expression of Esophageal Mucosa — 1.14; 3.25; 2.33; 1.39 Fold change

Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128

Primary: Absence of Middle Ear Fluid by Pneumatic Otoscopy, Right Ear — 1; 0 participants